成药市场：依产品类型、通路和地区划分

预计到 2026 年，非处方成药市场规模将达到 586.5 亿美元，到 2033 年将达到 988.7 亿美元。预计从 2026 年到 2033 年，其复合年增长率将达到 8.54%。

非处方药（OTC）是处方笺无需医疗专业人员处方即可直接出售给消费者的药物。这是因为药剂师依法有权在没有处方笺下出售这些药物。只要按照标籤说明并在医疗专业人员的指导下使用，成药都是安全有效的。成药即可轻鬆治愈某些疾病。

市场动态

疾病负担加重、对自我治疗成药）的需求不断增长、自我用药的趋势日益明显、COVID-19 大流行以及製药公司从处方药转向成药的趋势，预计将成为预测期内推动全球成药市场增长的主要因素。

2022年6月，Glenmark Pharmaceuticals从美国Wockhart Pharmaceuticals收购了部分已通过核准的学名药处方成药。该公司在声明中表示，此次收购包括已通过核准的简化新药申请（ANDA），用于治疗和预防胃溃疡和肠溃疡的法莫替丁片（10毫克和20毫克）。

2020年7月，诺华宣布了一项新计划，旨在帮助低收入和中低收入国家的患者获得价格合理的药物，以治疗新冠肺炎的主要症状。在疫苗和根治性治疗方法尚未问世的情况下，这显得尤为重要。诺华的新冠肺炎产品系列包括来自山德士部门的15种学名药成药和非处方药，旨在满足低收入和中低收入国家治疗新冠肺炎症状患者的迫切需求。

本报告的主要特点

• 本报告指出了各个细分市场的潜在商机，并描述了该市场中一系列有吸引力的投资提案。
• 此外，它还提供了有关市场驱动因素和限制因素、机会、新产品发布和核准、市场趋势、区域展望以及主要企业采取的竞争策略的重要见解。
• 本节根据以下参数，对全球成药)市场的主要企业进行介绍：公司概况、产品系列、主要亮点、财务表现和策略。
• 本报告中的见解将使负责人和企业经营团队能够就未来的产品发布、产品线更新、市场扩张和行销策略做出明智的决策。
• 《全球成药市场》报告面向该行业的众多相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
• 相关人员可以透过分析全球成药)市场中使用的各种策略矩阵来促进决策。

目录

第一章：分析目标与假设

• 分析目的
• 先决条件
• 简称

第二章 市场展望

• 报告说明
  • 市场定义和范围
• 执行摘要
• Coherent Opportunity Map（COM）

第三章：市场动态、监管与趋势分析

• 市场动态
  • 促进因素
  • 阻碍因素
  • PEST分析
  • 波特五力分析
  • 市场机会
  • 法规环境
  • 主要进展
  • 产业趋势

第四章：全球成药市场：依产品类型划分（2026-2033 年）

• 治疗咳嗽、感冒和流感的产品
• 止痛药
• 皮肤科产品
• 胃药
• 维他命
• 矿物质补充剂（VMS）
• 减重和饮食产品
• 眼科产品
• 助眠剂
• 其他产品类型

第五章：全球成药市场：依分销管道划分（2026-2033 年）

• 医院药房
• 零售药房
• 网路药房
• 其他分销管道

第六章：全球成药市场：按地区划分（2026-2033 年）

• 北美洲
  • 我们
  • 加拿大
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲
• 欧洲
  • 英国
  • 德国
  • 义大利
  • 法国
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韩国
  • 亚太其他地区
• 中东
  • 海湾合作委员会国家
  • 以色列
  • 其他中东国家
• 非洲
  • 南非
  • 北非
  • 中非

第七章 竞争情势

• 热图分析
• 市占率分析（3x3矩阵）
• 公司简介
  • Pfizer Inc.
  • Perrigo Company PLC
  • GlaxoSmithKline PLC
  • Mylan NV
  • Bayer AG
  • Reckitt Benckiser Group PLC
  • Johnson and Johnson
  • Sanofi
  • Takeda Pharmaceutical Company Ltd.

第八章 分析师建议

• 机会
• 分析师意见
• Coherent Opportunity Map (COM)

第九章 参考文献与分析方法

• 参考
• 分析方法

Over The Counter Drugs Market is estimated to be valued at USD 58.65 Bn in 2026 and is expected to reach USD 98.87 Bn by 2033, growing at a compound annual growth rate (CAGR) of 8.54% from 2026 to 2033.

Over-the-counter (OTC) drugs are medicines sold directly to a consumer without a requirement for a prescription (without a prescription) from the healthcare professional, as they are legally allowed to be sold by pharmacists without a prescription. When people follow the directions on the label and as directed by a health care professional, over-the-counter medicines are both safe and effective. Over-the-counter drugs treat a variety of illnesses and their symptoms and help cure some diseases simply and without the cost of seeing a doctor.

Market Dynamics

Increase in disease burden, increase in demand for OTC drugs, rising trend of self-medication, the outbreak of COVID-19, and inclination of pharma companies toward OTC drugs from RX drugs are major factors expected to drive growth of the global during the counter drugs market over the forecast period.

In June 2022, Glenmark Pharmaceuticals Ltd. acquired the approved generic versions of certain over-the-counter drugs from Wockhardt Ltd. in the U.S. The acquisition includes the approved abbreviated new drug applications (ANDAs) for famotidine tablets, 10 mg and 20 mg used to treat and prevent ulcers in the stomach and intestine, the company said in a statement.

In July 2020, Novartis announced a new initiative to help patients in low-income and lower-middle-income countries access affordable medicines to treat the major symptoms of COVID-19, a critical need in the absence of a vaccine or curative treatment. The Novartis COVID-19 portfolio includes 15 generic and OTC medicines from Sandoz division addresses urgent unmet needs of low- and lower-middle-income countries to treat patients with COVID-19 symptoms.

Key features of the study

• This report provides in-depth analysis of the global over the counter drugs market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global over the counter drugs market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Pfizer Inc., Perrigo Company PLC, GlaxoSmithKline PLC, Mylan NV, Bayer AG, Reckitt Benckiser Group PLC, Johnson and Johnson, Sanofi, and Takeda Pharmaceutical Company Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global over the counter drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global over the counter drugs market.

Market Segmentation

• By Product Type
  • Cough, Cold, and Flu Products
  • Analgesics
  • Dermatology Products
  • Gastrointestinal Products
  • Vitamins
  • Mineral and Supplements (VMS)
  • Weight-loss/Dietary Products
  • Ophthalmic Products
  • Sleeping Aids
  • Other Product Types
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacy
  • Other Distribution Channels
• By Regional Insights:
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • Pfizer Inc.
  • Perrigo Company PLC
  • GlaxoSmithKline PLC
  • Mylan NV
  • Bayer AG
  • Reckitt Benckiser Group PLC
  • Johnson and Johnson
  • Sanofi
  • Takeda Pharmaceutical Company Ltd.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Product Type
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • PEST Analysis
  • PORTER's Five Forces Analysis
  • Market Opportunities
  • Regulatory Scenario
  • Key Developments
  • Industry Trend

4. Global Over the Counter Drugs Market, By Product Type, 2026-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Cough, Cold, and Flu Products
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Analgesics
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Dermatology Products
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Gastrointestinal Products
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Vitamins
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Mineral and Supplements (VMS)
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Weight-loss/Dietary Products
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Ophthalmic Products
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Sleeping Aids
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Other Product Types
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends

5. Global Over the Counter Drugs Market, By Distribution Channel, 2026-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Hospital Pharmacies
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Retail Pharmacies
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Online Pharmacy
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Other Distribution Channels
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends

6. Global Over the Counter Drugs Market, By Region, 2026-2033, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, For Region, 2021 - 2033
• North America
  • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
  • Y-o-Y Growth Analysis, For Country, 2021 - 2033
  • Market Size and Forecast, By Product Type, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
  • Y-o-Y Growth Analysis, For Country, 2021 - 2033
  • Market Size and Forecast, By Product Type, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
  • Y-o-Y Growth Analysis, For Country, 2021 - 2033
  • Market Size and Forecast, By Product Type, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
  • Y-o-Y Growth Analysis, For Country, 2021 - 2033
  • Market Size and Forecast, By Product Type, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
  • Y-o-Y Growth Analysis, For Country, 2021 - 2033
  • Market Size and Forecast, By Product Type, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Market Share Analysis, By Country/Region, 2025, 2028 and 2033 (%)
  • Y-o-Y Growth Analysis, For Country/Region, 2021 - 2033
  • Market Size and Forecast, By Product Type, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

7. Competitive Landscape

• Heat Map Analysis
• Market Share Analysis (3x3 Matrix)
• Company Profiles
  • Pfizer Inc.
    • Company Overview
    • Product Type Portfolio
    • Recent Developments/Updates
  • Perrigo Company PLC
    • Company Overview
    • Product Type Portfolio
    • Recent Developments/Updates
  • GlaxoSmithKline PLC
    • Company Overview
    • Product Type Portfolio
    • Recent Developments/Updates
  • Mylan NV
    • Company Overview
    • Product Type Portfolio
    • Recent Developments/Updates
  • Bayer AG
    • Company Overview
    • Product Type Portfolio
    • Recent Developments/Updates
  • Reckitt Benckiser Group PLC
    • Company Overview
    • Product Type Portfolio
    • Recent Developments/Updates
  • Johnson and Johnson
    • Company Overview
    • Product Type Portfolio
    • Recent Developments/Updates
  • Sanofi
    • Company Overview
    • Product Type Portfolio
    • Recent Developments/Updates
  • Takeda Pharmaceutical Company Ltd.
    • Company Overview
    • Product Type Portfolio
    • Recent Developments/Updates

8. Analyst Recommendation

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

9. Section

• References
• Research Methodology
• About Us and Sales Contact